Peripheral T-Cell Lymphoma Drugs Market Size 2032 | Eisai, Solasia Pharma, CerRx, Kura Oncology, HUYA Bioscience International, Quintiles, Inc, Verastem, Genor Biopharma, Celgene Corporation, and others.

DelveInsight's "Peripheral T-cell Lymphoma Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of top oncogenic drivers/biomarkers in Peripheral T-cell Lymphoma, historical and forecasted epidemiology as well as the Peripheral T-cell Lymphoma Market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Key Takeaways from the Peripheral T-Cell Lymphoma Market Report
• As per Ngu and Savage (2023), PTCL accounts for about 10-15% of all NHL cases. Secondary findings suggest that about 8,000-12,000 people in the United States are diagnosed with PTCL every year.
• As per SEER 2008-2017, PTCL incidence was 1.2/100,000 in the United States.
• A study in Spain by Martín García-Sancho et al. (2023) quoted that ~15% of patients accounted for Stage I-II, and 85% fell under Stage III-IV.
• According to a study in the United States by Abramson et al. (2014), out of 300 patients, Stage I account for 14%, Stage II accounts for 11%, Stage III account for 23%, and Stage IV account for 48%. Most patients (71%) presented with advanced-stage disease (Ann Arbor Stage III-IV).
• As per SEER (2020), PTCL-NOS, AITL, ALCL, hepatosplenic TCL, and enteropathy-type intestinal TCL accounted for 38%, 14%, 17%, 1.1%, and 1.3%, respectively.
• The leading Peripheral T-Cell Lymphoma Companies such as Eisai, Solasia Pharma, CerRx, Kura Oncology, HUYA Bioscience International, Quintiles, Inc, Verastem, Genor Biopharma, Celgene Corporation, and others.
• Promising Peripheral T-Cell Lymphoma Therapies such as Alemtuzumab (Campath-1H), Systemic therapy, SHR2554/CHOP, lacutamab, Chidamide, cyclophosphamide, adriacin, and others.

Discover which therapies are expected to grab the Peripheral T-Cell Lymphoma Market Share @ Peripheral T-Cell Lymphoma Market Outlook- https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphoma-ptcl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Peripheral T-Cell Lymphoma Overview
Peripheral T-cell lymphoma (PTCL) is a type of non-Hodgkin lymphoma (NHL) that originates from mature T-cells or natural killer (NK) cells. It is a relatively rare and diverse group of lymphomas, characterized by its aggressive nature and tendency to involve lymph nodes and other organs outside of the lymphatic system.

Peripheral T-Cell Lymphoma Epidemiology Insights
PTCL-NOS is more prevalent in the United States and Europe, and ATLL and NKTCL are more prevalent in Asia. ATLL was frequent in Japan but was not found in other Asian countries, whereas NKTCL made up 44% of the cases in Asia, excluding Japan. ALCL, ALK-positive, was most common in North America, whereas enteropathy-type PTCL was most common in Europe.
• Total Peripheral T-Cell Lymphoma Incident cases
• Peripheral T-Cell Lymphoma Stage-specific Incident Cases
• Peripheral T-Cell Lymphoma Subtype-specific Incident Cases
• Peripheral T-Cell Lymphoma CD30 Expression in US

Download the report to understand which factors are driving Peripheral T-Cell Lymphoma Epidemiology trends @ Peripheral T-Cell Lymphoma Epidemiological Insights- https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphoma-ptcl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Peripheral T-Cell Lymphoma Marketed Drugs

• DARVIAS (darinaparsin): Solasia Pharma
Darinaparsin (SP-02), an organoarsenic compound with anticancer activity, is a novel mitochondrial-targeted agent being developed for treating various hematologic and solid tumors. The proposed mechanism of action of the drug involves the disruption of mitochondrial function, increased production of reactive oxygen species, and modulation of intracellular signal transduction pathways. Darinaparsin exerts an anticancer effect by inducing cell cycle arrest and apoptosis. In June 2022, Solasia Pharma announced that DARVIAS had been approved for R/R PTCL by the MHLW later.

• REMITORO (denileukin diftitox [genetical recombination]): Eisai
REMITORO is a fusion protein consisting of interleukin-2 (IL-2) and a partial sequence of diphtheria toxin and specifically binds to the IL-2 receptor on the surface of tumoral lymphocytes. The antitumor efficacy of denileukin diftitox depends on the intracellular delivery of diphtheria toxin fragment, which inhibits protein synthesis and induces cell death.

Peripheral T-Cell Lymphoma Emerging Drugs
• COPIKTRA (duvelisib): Secura Bio
COPIKTRA (Duvelisib) is a targeted oral inhibitor of phosphoinositide 3-kinase. The phosphoinositide 3-kinase (PI3K) signaling pathway is a key regulator of cancer proliferation (rapid increase or spread) and metastasis (development of secondary growths away from a primary site of cancer). The PI3K pathway includes four Class I isoforms: alpha, beta, delta, and gamma (a, ß, d, and ?). The four isoforms play unique roles in the survival of different tumor types, with roles of some isoforms in creating supportive tumor microenvironments (TME). It is the first approved dual inhibitor of PI3K-d and PI3K-? and received approval as monotherapy from the FDA in September 2018 to treat patients with R/R chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies. In January 2023, Secura Bio announced that the European Commission (EC) issued an ODD for duvelisib for the treatment of patients with PTCL.

• Golidocitinib (DZD4205): Dizal Pharmaceuticals
Golidocitinib is a selective JAK1 inhibitor, with an IC50 of 73 nM, weakly inhibits JAK2 and shows inhibition on JAK3 (IC50, >14.7, >30 µM, respectively). Golidocitinib inhibits STAT3 phosphorylation in NCI-H 1975 cells with an IC50 of 161 nM. It has increasing antitumor effects and enhances the antitumor activity of osimertinib compared to treatment with osimertinib alone in mice bearing NCIH1975 cells. In May 2022, the company presented Phase I/II data at the European Hematology Association 2022 for golidocitnib - a selective JAK1 inhibitor, in R/R PTCL. Dizal is conducting Phase II pivotal clinical trials in the US, China, Australia, South Korea, and other countries and regions. According to findings from part B of the Phase II JACKPOT8 study published in Lancet Oncology treatment with golidocitinib elicited favorable benefits among patients with R/T PTCL. Golidocitinib produced an ORR of 44.3% and a complete response rate of 29.5% based on the independent review committee (IRC) assessment.

Peripheral T-Cell Lymphoma Market Insights
The Peripheral T-Cell Lymphoma therapeutics challenge remains as these are aggressive and rare cancers which are extremely diverse. Currently, newly diagnosed PTCL patients are usually treated with anthracycline based chemotherapy regimens. For most subtypes of PTCL, the initial treatment is typically a combination chemotherapy regimen, such as CHOP, CHOEP, or other multidrug regimens. Patients with relapsed disease are usually treated with combination chemotherapy followed by stem cell transplantation.

Peripheral T-Cell Lymphoma Drugs Uptake

• Linperlisib (YY-20394): Shanghai YingLi Pharmaceutical
Linperlisib (YY-20394) is a highly selective and potent PI3Kδ inhibitor with a favorable safety profile,encouraging anti-tumor activities and promising PK and pharmaceutical properties as an oral once-a-dayagent in clinical development. Preliminary results of single-agent linperlisib from a R/R PTCL Phase Ib study showed an ORR of 70%with 33% CRs for this difficult-to-treat and aggressive form of lymphoma.

• Golidocitinib (DZD4205): Dizal Pharmaceutical
Golidocitinib is a selective JAK1 inhibitor, with an IC50 of 73 nM, weakly inhibits JAK2 and showsinhibition on JAK3 (IC50, >14.7, >30 μM, respectively). Golidocitinib inhibits STAT3 phosphorylation inNCI-H 1975 cells with an IC50 of 161 nM.

• MT-101: Myeloid Therapeutics
MT-101 is the Company's first autologous CAR monocyte. It is designed to harness the ability of myeloidcells to penetrate into tumors and promote broad anti-tumor activity. MT-101 targets CD5, a surfacereceptor that is present in greater than 75% of PTCL.

Peripheral T-Cell Lymphoma Treatment Landscape
Peripheral T-Cell Lymphoma treatment aims to cure and includes the use of combination chemotherapy regimens, localized radiotherapy, stem cell transplant steroid therapy, etc. It is most often treated with a combination of chemotherapies which includes CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and CHOEP or EPOCH (etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone). In some cases, a stem cell or bone marrow transplant is recommended at the end of combination chemotherapy.

Peripheral T-cell Lymphoma Market Outlook
As more targetable mutations are discovered, and new targeted drugs are developed, patients and oncologists will have an expanding array of treatment options. Given the rapid pace of drug approvals, it is important to pause and ensure sufficient data supports the use of specific agents in the appropriate treatment settings, including adjuvant, consolidation, first-line, or subsequent therapy.

Scope of the Peripheral T-Cell Lymphoma Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Peripheral T-Cell Lymphoma Companies- Eisai, Solasia Pharma, CerRx, Kura Oncology, HUYA Bioscience International, Quintiles, Inc, Verastem, Genor Biopharma, Celgene Corporation, and others.
• Peripheral T-Cell Lymphoma Therapies- Alemtuzumab (Campath-1H), Systemic therapy, SHR2554/CHOP, lacutamab, Chidamide, cyclophosphamide, adriacin, and others.
• Peripheral T-Cell Lymphoma Market Dynamics: Peripheral T-Cell Lymphoma Market Drivers and Barriers
• Peripheral T-Cell Lymphoma Unmet Needs, KOL's views, Analyst's views, Peripheral T-Cell Lymphoma Market Access and Reimbursement

Discover more about Peripheral T-Cell Lymphoma Drugs in development @ Peripheral T-Cell Lymphoma Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphoma-ptcl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. Epidemiology and Market Forecast Methodology
6. Peripheral T-cell Lymphoma Market Overview at a Glance in the 7MM
7. Disease Background and Overview
8. Treatment and Management of PTCL
9. Treatment Guidelines
10. Epidemiology and Patient Population of PTCL in the 7MM
11. Patient Journey
12. Key Endpoints in PTCL
13. Marketed Drugs
14. Emerging Therapies
15. Peripheral T-cell Lymphoma: 7MM Analysis
16. Unmet Needs
17. SWOT Analysis
18. KOL Views
19. Market Access and Reimbursement
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Yash Bhardwaj
DelveInsight
+91 9650213330

This release was published on openPR.